Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)

Gilead Sciences (GILD) posted Amortizatization of Intangibles of $596.0 million for Q1 2026, little changed quarter-over-quarter from $597.0 million in Q4 2025, and down 0.5% year-on-year from $599.0 million in Q1 2025.

Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Amortizatization of Intangibles for 18 consecutive years, with $596.0 million the latest figure, recorded in Q1 2026.

  • Amortizatization of Intangibles for Q1 2026 came in at $596.0 million, down 0.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (changed 0.08% YoY), and the FY2025 annual result was $2.4 billion, changed 0.17% from the prior year.
  • Amortizatization of Intangibles was $596.0 million for Q1 2026 at Gilead Sciences, roughly flat from $597.0 million in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $599.0 million in Q1 2025 and troughed at $445.0 million in Q1 2022.
  • Average Amortizatization of Intangibles over 5 years is $558.3 million, with a median of $596.0 million recorded in 2024.
  • Year-over-year, Amortizatization of Intangibles surged 34.38% in 2023 and fell 0.5% in 2026.
  • Over 5 years, Amortizatization of Intangibles stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then advanced by 0.17% to $598.0 million in 2024, then retreated by 0.17% to $597.0 million in 2025, then fell by 0.17% to $596.0 million in 2026.
  • Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $596.0 million in Q1 2026, $597.0 million in Q4 2025, and $596.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. of Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 1.70 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 931.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 596.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 107.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 596.00 Mn
Mar 31, 2026 596.00 Mn
Dec 31, 2025 597.00 Mn
Dec 31, 2025 597.00 Mn
Sep 30, 2025 596.00 Mn
Sep 30, 2025 596.00 Mn
Jun 30, 2025 598.00 Mn
Jun 30, 2025 598.00 Mn
Mar 31, 2025 599.00 Mn
Mar 31, 2025 599.00 Mn
Dec 31, 2024 598.00 Mn
Dec 31, 2024 598.00 Mn
Sep 30, 2024 596.00 Mn
Sep 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Jun 30, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn
Mar 31, 2024 596.00 Mn
Dec 31, 2023 597.00 Mn
Dec 31, 2023 597.00 Mn